Prof Chang's research focuses on polymer modification and application in the medical fields, liposome-based drug delivery systems for skin and bone treatment, and mechanobiology of intervertebral disc cells.

Professor Dass has been in the cancer R&D field for the past three decades, amassing experience in industry (biotech), hospitals, and academia. His lab is a leader in the field of PEDF research in oncology. Currently he is lab leader and also the Director of Grad Res at the Curtin Med Sch, at Curtin University, and is affiliated with Silpakorn University.

Phuong Nguyen obtained her PhD in Medicinal Chemistry at the University of Wollongong in Australia in 2015. She is currently an Associate Professor in School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh city, Vietnam. Her research focuses on computer-aided drug discovery and development, including molecular modeling, design and optimization of pharmaceuticals formulations.

Reymark Ereje is an Assistant Professor of Chemistry at the Department of Physical Sciences, College of Science, University of the Philippines Baguio. He obtained his Bachelor’s degree in chemistry from the University of the Philippines Visayas in 2016. He finished his Master of Science in Chemistry (Organic Chemistry) degree from the Chulalongkorn University, Bangkok, Thailand last July 2023 where he is recipient of the ASEAN Scholarship and the UP FRASDP Fellowship. He specializes in Synthetic Organic Chemistry, Medicinal Chemistry and Small Molecule Drug Discovery. His current interest is in small molecule research for anticancer applications. He recently published his paper titled “Diversity-Oriented Strategy (DOS) for the Efficient Synthesis of Benzofuro[2,3]pyridine Derivatives with Anticancer Activity” and was selected as Cover Feature in the 3rd issue of ChemMedChem journal in 2025.

Dr. Johnson is a Postdoctoral Research Fellow at the Asbestos and Dust Diseases Research Institute (ADDRI), Sydney, Australia, where he is currently specialising in biomarker discovery-based research aimed to facilitate an improved and early diagnosis of pleural mesothelioma. Dr. Johnson attained both his BSc (Hons) and PhD from the Western Sydney University in 2011 and 2015, respectively, where he carried out research relating to anti-cancer drug discovery, characterisation and screening. Since commencing his role at the ADDRI in 2019, Dr Johnson has gained sound experience in novel circular RNA (circRNA) and extracellular vesicle (EV) biomarker discovery in the context of pleural mesothelioma diagnostics. Dr Johnson has published his research in reputable peer-reviewed oncology-themed journals and has presented his work at national and international asbestos-related disease conferences, and international asbestos-related disease training workshops held in the Philippines, Fiji and Jakarta.